{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:26:12Z","timestamp":1792841172404,"version":"4.5.0"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Rituximab and azathioprine are used to induce or maintain remission in patients with ANCA-associated vasculitis (AAV). We evaluated the incidence of serious infections and infection-related deaths in patients with AAV treated with rituximab and azathioprine, during the maintenance of remission period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched PubMed and EMBASE for randomized clinical trials (RCTs) and observational studies evaluating immunosuppressive agents in patients with AAV. We defined serious or severe infections according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The study was registered on PROSPERO (CRD42022366269).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From 1,265 abstracts, we identified 21 studies (7 RCTs and 14 observational), with relevant data. We included data from 1,284 and 2,938 individuals for assessment in our primary and secondary outcomes, respectively. The overall cumulative incidence of serious infections was 15.99% (CI 95%: 6.95\u201327.53%) during the total follow-up period (induction and maintenance) and 7.62% (CI 95%: 4.43\u201311.43%) during the maintenance period. Additionally, we found a 0.49% overall case fatality rate (CI 95%: 0.02\u20131.37%) and a 0.09% infection-related mortality rate (CI 95%: 0.00\u20130.51%) during maintenance treatment. Notably, we found a 14.61% (CI 95%: 10.19\u201319.61%) cumulative incidence of serious infections among patients who received rituximab and a 5.93% (CI 95%: 1.19\u201313.26%) cumulative incidence of serious infections among patients who received azathioprine during maintenance. Moreover, the cumulative incidence of serious infections during the total follow-up period (induction and maintenance) was 20.81% (CI 95%:4.56\u201343.70%) for the combination of cyclophosphamide and azathioprine and 14.12% (CI 95%: 5.20\u201326.00%) for rituximab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The cumulative incidence of serious infections during total follow-up and maintenance was within expected limits, while fatal infections during maintenance treatment were uncommon. Additionally, treatment with rituximab for both induction and maintenance did not exceed the anticipated by previous studies incidence of serious infections. Clinical practice and long-term follow up data are needed to corroborate these findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p>Identifier: PROSPERO (CRD42022366269).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1110548","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T05:49:37Z","timestamp":1677649777000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Incidence of serious infections in patients with ANCA-associated vasculitis receiving immunosuppressive therapy: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"10","author":[{"given":"Athanasios","family":"Vassilopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanos","family":"Vassilopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markos","family":"Kalligeros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Shehadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Mylonakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"Anca-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/eci.12410","article-title":"Frequency, risk factors and prophylaxis of infection in anca-associated vasculitis","volume":"45","author":"Kronbichler","year":"2015","journal-title":"Eur J Clin Invest."},{"key":"B3","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in anca-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for anca-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA."},{"key":"B8","doi-asserted-by":"publisher","first-page":"609924","DOI":"10.3389\/fmed.2021.609924","article-title":"The role of mycophenolate mofetil for the induction of remission in anca-associated vasculitis: a meta-analysis","volume":"8","author":"Xiong","year":"2021","journal-title":"Front Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2215\/CJN.07300712","article-title":"Lymphopenia and treatment-related infectious complications in anca-associated vasculitis","volume":"8","author":"Goupil","year":"2013","journal-title":"Clin J Am Soc Nephrol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.2147\/DDDT.S139248","article-title":"Current perspective on rituximab in rheumatic diseases","volume":"11","author":"Schioppo","year":"2017","journal-title":"Drug Des Devel Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ejim.2013.02.008","article-title":"Using cyclophosphamide in inflammatory rheumatic diseases","volume":"24","author":"Brummaier","year":"2013","journal-title":"Eur J Intern Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ctrv.2015.11.005","article-title":"Low dose cyclophosphamide: mechanisms of T cell modulation","volume":"42","author":"Madondo","year":"2016","journal-title":"Cancer Treat Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","article-title":"Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology","volume":"16","author":"Broen","year":"2020","journal-title":"Nat Rev Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"102505","DOI":"10.1016\/j.autrev.2020.102505","article-title":"Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: a meta-analysis","volume":"19","author":"Thery-Casari","year":"2020","journal-title":"Autoimmun Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The prisma 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"B16","unstructured":"Common Terminology Criteria for Adverse Events (Ctcae) Version 5.2017"},{"key":"B17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","article-title":"The levels of evidence and their role in evidence-based medicine","volume":"128","author":"Burns","year":"2011","journal-title":"Plast Reconstr Surg."},{"key":"B18","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"B19","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"Robins-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ."},{"key":"B20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias visualization (robvis): an r package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods."},{"key":"B21","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"Grade: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ."},{"key":"B22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials."},{"key":"B23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health."},{"key":"B24","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root","volume":"21","author":"Freeman","year":"1950","journal-title":"Ann Math Statist."},{"key":"B25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10157-013-0830-8","article-title":"Epidemiology and clinical features of systemic vasculitis","volume":"17","author":"Scott","year":"2013","journal-title":"Clin Exp Nephrol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/rheumatology\/ker454","article-title":"The contrasting epidemiology of granulomatosis with polyangiitis (wegener's) and microscopic polyangiitis","volume":"51","author":"Watts","year":"2012","journal-title":"Rheumatology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/1536867X0800800403","article-title":"Meta-regression in stata","volume":"8","author":"Harbord","year":"2008","journal-title":"Stata J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ."},{"key":"B29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jama.295.6.676","article-title":"Comparison of two methods to detect publication bias in meta-analysis","volume":"295","author":"Peters","year":"2006","journal-title":"JAMA."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for anca-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in anca-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2215\/CJN.11801018","article-title":"Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis: randomized, controlled trial","volume":"14","author":"Tuin","year":"2019","journal-title":"Clin J Am Soc Nephrol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain anca-associated vasculitis remission: results of a multicentre, randomised controlled, phase iii trial (Mainritsan2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/rheumatology\/kem029","article-title":"Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in wegener's granulomatosis","volume":"46","author":"Metzler","year":"2007","journal-title":"Rheumatology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2215\/CJN.06010809","article-title":"Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement\u2013a prospective, open-label pilot trial","volume":"5","author":"Silva","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3899\/jrheum.110143","article-title":"Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis","volume":"39","author":"Roubaud-Baudron","year":"2012","journal-title":"J Rheumatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/art.10459","article-title":"High rate of renal relapse in 71 patients with wegener's granulomatosis under maintenance of remission with low-dose methotrexate","volume":"47","author":"Reinhold-Keller","year":"2002","journal-title":"Arthritis Rheum."},{"key":"B38","doi-asserted-by":"publisher","first-page":"736","DOI":"10.2215\/CJN.07340713","article-title":"Long-term maintenance therapy using rituximab-induced continuous b-cell depletion in patients with anca vasculitis","volume":"9","author":"Pendergraft","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.arcmed.2007.07.006","article-title":"Mycophenolate mofetil in low doses stabilizes and improves antineutrophil cytoplasmic antibody-associated vasculitis and lupus nephritis","volume":"39","author":"Kazderova","year":"2008","journal-title":"Arch Med Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/injr.injr_138_18","article-title":"Rituximab in relapsed\/refractory antineutrophil cytoplasmic antibody associated vasculitis: a single-center prospective observational study","volume":"14","author":"Gayatri","year":"2019","journal-title":"Indian J Rheumatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1002\/art.1780391215","article-title":"Therapy for the maintenance of remission in sixty-five patients with generalized wegener's granulomatosis. methotrexate versus trimethoprim\/sulfamethoxazole","volume":"39","author":"de Groot","year":"1996","journal-title":"Arthritis Rheum."},{"key":"B42","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/rheumatology\/ket381","article-title":"Rituximab for induction and maintenance treatment of anca-associated vasculitides: a multicentre retrospective study on 80 patients","volume":"53","author":"Charles","year":"2014","journal-title":"Rheumatology."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1007\/s10067-022-06192-1","article-title":"Rituximab treatment in anca-associated vasculitis patients: outcomes of a real-life experience from an observational cohort","volume":"41","author":"Carranza-Enr\u00edquez","year":"2022","journal-title":"Clin Rheumatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/rheumatology\/ket257","article-title":"Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre","volume":"52","author":"Besada","year":"2013","journal-title":"Rheumatology."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1002\/art.38744","article-title":"Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (wegener's): a retrospective single-center study","volume":"66","author":"Azar","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00296-018-3928-1","article-title":"Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies","volume":"38","author":"Ayan","year":"2018","journal-title":"Rheumatol Int."},{"key":"B47","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13075-021-02452-8","article-title":"Serious infections in anca-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients","volume":"23","author":"Thomas","year":"2021","journal-title":"Arthritis Res Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/art.20240","article-title":"Mycophenolate mofetil for remission maintenance in the treatment of wegener's granulomatosis","volume":"51","author":"Langford","year":"2004","journal-title":"Arthritis Rheum."},{"key":"B49","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for anca-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for anca-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in anca-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in anca-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in anca-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/ndt\/gfw211","article-title":"Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial","volume":"31","author":"Sanders","year":"2016","journal-title":"Nephrol Dial Transplant."},{"key":"B58","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/art.40802","article-title":"Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled study","volume":"71","author":"Jayne","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000447018","article-title":"Outcomes of elderly patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis treated with immunosuppressive therapy","volume":"133","author":"Judge","year":"2016","journal-title":"Nephron."},{"key":"B60","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in anca vasculitis","volume":"3","author":"Cortazar","year":"2018","journal-title":"Kidney Int Rep."},{"key":"B61","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaut.2014.03.002","article-title":"Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). results of a single-center cohort study on 66 patients","volume":"50","author":"Calich","year":"2014","journal-title":"J Autoimmun."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for anca-associated vasculitis","volume":"54","author":"Alberici","year":"2015","journal-title":"Rheumatology."},{"key":"B63","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10067-020-05261-7","article-title":"Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis-a real-life experience","volume":"40","author":"Mittal","year":"2021","journal-title":"Clin Rheumatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.3899\/jrheum.131426","article-title":"Predictors for mortality in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a study of 398 chinese patients","volume":"41","author":"Lai","year":"2014","journal-title":"J Rheumatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.autrev.2018.01.022","article-title":"Mortality in systemic necrotizing vasculitides: a retrospective analysis of the french vasculitis study group registry","volume":"17","author":"Jardel","year":"2018","journal-title":"Autoimmun Rev."},{"key":"B66","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223335.","article-title":"2022 eular recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","author":"Fragoulis","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12874-021-01310-0","article-title":"Most published meta-regression analyses based on aggregate data suffer from methodological pitfalls: a meta-epidemiological study","volume":"21","author":"Geissb\u00fchler","year":"2021","journal-title":"BMC Med Res Methodol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1110548\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T05:49:42Z","timestamp":1677649782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1110548\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":68,"alternative-id":["10.3389\/fmed.2023.1110548"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1110548","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]},"article-number":"1110548"}}